

Fibrillazione Atriale: L'Ablazione quando e perchè

Riccardo Riccardi

Divisione di Cardiologia Ospedale Agnelli di Pinerolo

*Dal caso clinico
alle nuove strategie
terapeutiche:*
confronto tra Cardiologi Ospedalieri
e Medici di Medicina Generale
Responsabili del Convegno:
Dott. Ferdinando Varbella, Dott. Riccardo Riccardi,
Dott.ssa Maria Milano



Sabato 23 Settembre 2017
IL MULINO DI PIOSSASCO
Sala Teatro

23 Settembre 2017

In Italia

- 1 - 1.5 milioni con FA
- 8-10.000 ablazioni all'anno
- 20-30% asintomatici
- 20-30% Recidive di FA post Ablazione



I 3 motivi per cui il Ritmo Sinusale è meglio della Fibrillazione Atriale

- Se siamo stati creati in ritmo sinusale ci sarà un motivo
- Se in 2 milioni di anni l'uomo si è evoluto in ritmo sinusale ci sarà un motivo
- Se gli animali che vivono più a lungo hanno mediamente una frequenza minore ci sarà un motivo



I 3 motivi per cui il Controllo del Ritmo è meglio del Controllo della Frequenza

- Se siamo stati creati in ritmo sinusale ci sarà un motivo

Fede

- Se in 2 milioni di anni l'uomo si è evoluto in ritmo sinusale ci sarà un motivo

Razionale

- Se gli animali che vivono più a lungo hanno mediamente una frequenza minore ci sarà un motivo

Empirica



Ritmo sinusale è meglio della Fibrillazione Atriale?

Si vive più a lungo

Si vive meglio

Ci ammaliamo di meno




Ritmo sinusale è meglio della Fibrillazione Atriale?

Si vive più a lungo




AF and Risk of Death: Framingham


N = 5209




75-94 anni



Framingham Study Circulation 1998;98;946-952






Framingham Study Circulation 1998;98;946-952



AFFIRM: DRUG TREATMENT

NEJM 2002, 347:23



No. of DEATHS

| | | number (percent) | | | | |
|----------------|---|------------------|---------|----------|----------|----------|
| Rhythm control | 0 | 80 (4) | 175 (9) | 257 (13) | 314 (18) | 352 (24) |
| Rate control | 0 | 78 (4) | 148 (7) | 210 (11) | 275 (16) | 306 (21) |

AFFIRM: DRUG TREATMENT

NEJM 2002, 347:23

| DRUG | RATE-CONTROL GROUP | | RHYTHM-CONTROL GROUP | |
|----------------|-------------------------------|-----------------------|-------------------------------|-----------------------|
| | USED DRUG FOR INITIAL THERAPY | USED DRUG AT ANY TIME | USED DRUG FOR INITIAL THERAPY | USED DRUG AT ANY TIME |
| | no. of patients (%) | | | |
| Rate control | | | | |
| Data available | 1957 | 2027 | 1266 | 2033 |
| Digoxin | 949 (48.5) | 1422 (70.6) | 417 (32.9) | 1106 (54.4) |
| Beta-blocker | 915 (46.8) | 1380 (68.1) | 276 (21.8) | 1008 (49.6) |
| Diltiazem | 583 (29.8) | 935 (46.1) | 198 (15.6) | 610 (30.0) |
| Verapamil | 187 (9.6) | 340 (16.8) | 56 (4.4) | 204 (10.0) |
| Rhythm control | | | | |
| Data available | 1265 | 2027 | 1960 | 2033 |
| Amiodarone | 2 (0.2)† | 207 (10.2) | 735 (37.5) | 1277 (62.8) |
| Sotalol | 1 (0.1)† | 84 (4.1) | 612 (31.2) | 841 (41.4) |
| Propafenone | 2 (0.2)† | 45 (2.2) | 183 (9.3) | 294 (14.5) |
| Procainamide | 0 | 30 (1.5) | 103 (5.3) | 173 (8.5) |
| Quinidine | 2 (0.2)† | 14 (0.7) | 92 (4.7) | 151 (7.4) |
| Flecainide | 0 | 29 (1.4) | 88 (4.5) | 169 (8.3) |
| Disopyramide | 0 | 7 (0.3) | 42 (2.1) | 87 (4.3) |
| Moricizine | 0 | 2 (0.1) | 14 (0.7) | 35 (1.7) |
| Dofetilide | 0 | 5 (0.2) | | |
| | | | 12.8 | 21.9 |

Effects of Rhythm and Drugs in AFFIRM

Circulation

March 30, 2004

TABLE 3. Covariates Significantly Associated With Survival Results With Echocardiographic Data Excluded

| Covariate | <i>P</i> | HR | HR: 99% Confidence Limits | |
|--------------------------------------|----------|------|---------------------------|-------|
| | | | Lower | Upper |
| Age at enrollment* | <0.0001 | 1.06 | 1.04 | 1.08 |
| Coronary artery disease | <0.0001 | 1.65 | 1.31 | 2.07 |
| Congestive heart failure | <0.0001 | 1.83 | 1.45 | 2.32 |
| Diabetes | <0.0001 | 1.56 | 1.22 | 2.00 |
| Stroke or transient ischemic attack | <0.0001 | 1.54 | 1.17 | 2.05 |
| Smoking | <0.0001 | 1.75 | 1.29 | 2.39 |
| First episode of atrial fibrillation | 0.0067 | 1.27 | 1.01 | 1.58 |
| Sinus rhythm | <0.0001 | 0.54 | 0.42 | 0.70 |
| Warfarin use | <0.0001 | 0.47 | 0.36 | 0.61 |
| Digoxin use | <0.0001 | 1.50 | 1.18 | 1.89 |
| Rhythm-control drug use | 0.0005 | 1.41 | 1.10 | 1.83 |

*Per year of age.



Ritmo sinusale è meglio della Fibrillazione Atriale?


Si vive meglio



QUALITY OF LIFE SCORES

152 AF pts

SF-36
score




Modified from: Dorian JACC 2000

Ritmo sinusale è meglio della Fibrillazione Atriale?

Ci ammaliamo di meno



Risultati Test cognitivi



- La performance cognitiva dei pazienti con FA è peggiore rispetto a quella dei pazienti in Ritmo sinusale ($P < 0,01$).

Nangeroni , Riccardi GIC 2012


Prevalence of Silent Cerebral Ischemia in Paroxysmal and Persistent Atrial Fibrillation and Correlation With Cognitive Function

1994

Gaita *et al.*

Atrial Fibrillation and Silent Cerebral Ischemia

JACC Vol. 62, No. 21, 2013
November 19/26, 2013:1990-7



| Domains | Controls (N = 90) | PRX AF (N = 90) | PER AF (N = 90) | p PRX / controls | p PER / controls | p PRX / PER |
|---------------------------|-------------------|-----------------|-----------------|------------------|------------------|-------------|
| Domains | 92.4 ± 15.4 | 86.2 ± 13.8 | 82.9 ± 11.5 | < 0.01 | < 0.01 | 0.08 |
| 1-Immediate Memory | 95.6 ± 17.5 | 89.9 ± 14.7 | 87.1 ± 16.9 | 0.02 | < 0.01 | 0.24 |
| 2-Visuo-spatial abilities | 93.8 ± 16.7 | 89.9 ± 18.2 | 84.8 ± 14.8 | 0.14 | < 0.01 | 0.04 |
| 3-Language | 92.9 ± 11.4 | 88.8 ± 9.1 | 88.1 ± 8.7 | < 0.01 | < 0.01 | 0.59 |
| 4-Attention | 101.4 ± 21.2 | 96.6 ± 16.6 | 94.9 ± 15.6 | 0.09 | 0.02 | 0.47 |
| 5-Delayed memory | 93.5 ± 11.7 | 88.7 ± 14.7 | 87.7 ± 14 | 0.02 | < 0.01 | 0.64 |


Figure 2 Results of Cognitive Function Evaluation

Prevalence of Silent Cerebral Ischemia in Paroxysmal and Persistent Atrial Fibrillation and Correlation With Cognitive Function

1994

Gaita *et al.*
Atrial Fibrillation and Silent Cerebral Ischemia

JACC Vol. 62, No. 21, 2013
November 19/26, 2013:1990-7



JACC Vol. 62, No. 21, 2013
November 19/26, 2013:1990-7

Gaita *et al.* 1995
Atrial Fibrillation and Silent Cerebral Ischemia





Figure 2 Results of

Paroxysmal → Persistent AF


Atrial Fibrillation begets Atrial Fibrillation




Wijffels et al. Circulation 1995

Increased Number of Wavelets

Acute AF




Persistent AF




The First Days....

AERP



Wijffels et al. Circulation 1995



Come mantenere il Ritmo Sinusale




palliativa




radicale






Farmaci



Ablazione






The Atrial Fibrillation Ablation Pilot Study: a European Survey on Methodology and results of catheter ablation for atrial fibrillation conducted by the European Heart Rhythm Association


European Heart Journal (2014)









| | |
|-----------------------------|---|
| AF episode | An AF episode is defined as AF that is documented by ECG monitoring or intracardiac electrogram monitoring and has a duration of at least 30 s, or if less than 30 s, is present throughout the ECG monitoring tracing. The presence of subsequent episodes of AF requires that sinus rhythm be documented by ECG monitoring between AF episodes. |
| Chronic AF | Chronic AF has variable definitions and should not be used to describe populations of AF patients undergoing AF ablation. |
| Early persistent AF | Early persistent AF is defined as AF that is sustained beyond 7 days but is less than 3 months in duration. |
| Lone AF | Lone AF is a historical descriptor that is potentially confusing and should not be used to describe populations of patients with AF undergoing AF ablation. |
| Long-standing persistent AF | Long-standing persistent AF is defined as continuous AF of greater than 12 months' duration. |
| Paroxysmal AF | Paroxysmal AF is defined as AF that terminates spontaneously or with intervention within 7 days of onset. |
| Permanent AF | Permanent AF is defined as the presence of AF that is accepted by the patient and physician, and for which no further attempts to restore or maintain sinus rhythm will be undertaken. The term <i>permanent AF</i> represents a therapeutic attitude on the part of the patient and physician rather than an inherent pathophysiological attribute of AF. The term <i>permanent AF</i> should not be used within the context of a rhythm control strategy with antiarrhythmic drug therapy or AF ablation. |
| Persistent AF | Persistent AF is defined as continuous AF that is sustained beyond 7 days. |
| Silent AF | Silent AF is defined as asymptomatic AF diagnosed with an opportune ECG or rhythm strip. |







| | | | | |
|--------------|------------|------------|------------|------------|
| Parox | 22% | 39% | 39% | 0% |
| Perm | 0% | 8% | 33% | 59% |

Gaita Riccardi et al JACC 2001


Come mantenere il Ritmo Sinusale




**Gaita-Riccardi
Circulation 98**



**Haissaguerre-Jais
NEJM 1998**




**Gaita-Riccardi
Circulation 2005**



**Nademanee
Circulation 2005**




(a)




T. P. P. P.
© JHU 2017/AAAM


(b)




T. P. P. P.
© JHU 2017/AAAM



| Complication | Incidence | Cause | Clinical Presentation | Diagnostic Tools |
|-----------------------------|------------|--|---|--|
| Cardiac tamponade | 0.0–2.9% | TSP Linear lesions High RF power | Chest pain Tachycardia Dyspnea Abrupt hypotension/shock | TTE |
| TEs | 0.0–1.1% | Use of number of sheaths/catheters in the arterial system Wide disruption of LA endocardial surface | Neurological deficits Acute ischemia of different organs depending on the site of TEs | Head CT/MR imaging Different tools |
| PV stenosis | 0.0–0.5% | RF delivery inside PVs | Cough Dyspnea Hemoptysis Recurrent/drug-resistant pneumonia | TEE V/Q lung scan CT/MR imaging |
| PN injury | 0.1–0.5% | RF delivery at sites in close proximity to right/left PN (RSPV, SVC, etc.) | Dyspnea Cough Weakness Unilateral diaphragmatic paralysis | Fluoroscopy |
| Atrioesophageal fistula | 0.03–0.25% | RF delivery at posterior wall of LA | Fever Malaise Dysphagia Hematemesis/melena Neurological deficits Intermittent cardiac ischemia Septic shock | CT/MR imaging |
| Periesophageal vagal injury | 1.0% | Injury of periesophageal vagal plexus | Abdominal bloating Discomfort Pain | Gastroscopy and upper gastrointestinal investigation |




| Complication | Incidence | Cause | Clinical Presentation | Diagnostic Tools |
|-----------------------------|------------|--|---|--|
| Cardiac tamponade | 0.0–2.9% | TSP Linear lesions High RF power | Chest pain Tachycardia Dyspnea Abrupt hypotension/shock | TTE |
| TEs | 0.0–1.1% | Use of number of sheaths/catheters in the arterial system Wide disruption of LA endocardial surface | Neurological deficits Acute ischemia of different organs depending on the site of TEs | Head CT/MR imaging Different tools |
| PV stenosis | 0.0–0.5% | RF delivery inside PVs | Cough Dyspnea Hemoptysis Recurrent/drug-resistant pneumonia | TEE V/Q lung scan CT/MR imaging |
| PN injury | 0.1–0.5% | RF delivery at sites in close proximity to right/left PN (RSPV, SVC, etc.) | Dyspnea Cough Weakness Unilateral diaphragmatic paralysis | Fluoroscopy |
| Atrioesophageal fistula | 0.03–0.25% | RF delivery at posterior wall of LA | Fever Malaise Dysphagia Hematemesis/melena Neurological deficits Intermittent cardiac ischemia Septic shock | CT/MR imaging |
| Periesophageal vagal injury | 1.0% | Injury of periesophageal vagal plexus | Abdominal bloating Discomfort Pain | Gastroscopy and upper gastrointestinal investigation |



Indicazioni all'ablazione della FA

| | Recommendation | Class | LOE |
|--|--|-------|------|
| Indications for catheter ablation of atrial fibrillation | | | |
| A. Indications for catheter ablation of atrial fibrillation | | | |
| Symptomatic AF refractory or intolerant to at least one Class I or III antiarrhythmic medication | Paroxysmal: Catheter ablation is recommended. | I | A |
| | Persistent: Catheter ablation is reasonable. | IIa | B-NR |
| | Long-standing persistent: Catheter ablation may be considered. | IIb | C-LD |
| Symptomatic AF prior to initiation of antiarrhythmic therapy with a Class I or III antiarrhythmic medication | Paroxysmal: Catheter ablation is reasonable. | IIa | B-R |
| | Persistent: Catheter ablation is reasonable. | IIa | C-EO |
| | Long-standing persistent: Catheter ablation may be considered. | IIb | C-EO |


J Interv Card Electrophysiology 2017



Indicazioni all'ablazione della FA

| | Recommendation | Class | LOE |
|--|--|-------|------|
| Indications for catheter ablation of atrial fibrillation | | | |
| A. Indications for catheter ablation of atrial fibrillation | | | |
| Symptomatic AF refractory or intolerant to at least one Class I or III antiarrhythmic medication | Paroxysmal: Catheter ablation is recommended. | I | A |
| | Persistent: Catheter ablation is reasonable. | IIa | B-NR |
| | Long-standing persistent: Catheter ablation may be considered. | IIb | C-LD |
| Symptomatic AF prior to initiation of antiarrhythmic therapy with a Class I or III antiarrhythmic medication | Paroxysmal: Catheter ablation is reasonable. | IIa | B-R |
| | Persistent: Catheter ablation is reasonable. | IIa | C-EO |
| | Long-standing persistent: Catheter ablation may be considered. | IIb | C-EO |

J Interv Card Electrophysiology 2017



Indicazioni all'ablazione della FA

| | | | | |
|-----------------------------------|--|-----|------|--------------|
| Congestive heart failure | It is reasonable to use similar indications for AF ablation in selected patients with heart failure as in patients without heart failure. | IIa | B-R | [36–52] |
| Older patients (>75 years of age) | It is reasonable to use similar indications for AF ablation in selected older patients with AF as in younger patients. | IIa | B-NR | [53–59] |
| Hypertrophic cardiomyopathy | It is reasonable to use similar indications for AF ablation in selected patients with HCM as in patients without HCM. | IIa | B-NR | [60–62] |
| Young patients (<45 years of age) | It is reasonable to use similar indications for AF ablation in young patients with AF (<45 years of age) as in older patients. | IIa | B-NR | [63, 64] |
| Tachy-brady syndrome | It is reasonable to offer AF ablation as an alternative to pacemaker implantation in patients with tachy-brady syndrome. | IIa | B-NR | [33–35] |
| Athletes with AF | It is reasonable to offer high-level athletes AF as first-line therapy due to the negative effects of medications on athletic performance. | IIa | C-LD | [27, 28, 65] |
| Asymptomatic AF** | Paroxysmal: Catheter ablation may be considered in select patients.** | IIb | C-EO | [66, 67] |
| | Persistent: Catheter ablation may be considered in select patients. | IIb | C-EO | [68] |


J Interv Card Electrophysiology 2017



Indicazioni all'ablazione della FA

| | | | | |
|-----------------------------------|--|-----|------|--------------|
| Congestive heart failure | It is reasonable to use similar indications for AF ablation in selected patients with heart failure as in patients without heart failure. | IIa | B-R | [36–52] |
| Older patients (>75 years of age) | It is reasonable to use similar indications for AF ablation in selected older patients with AF as in younger patients. | IIa | B-NR | [53–59] |
| Hypertrophic cardiomyopathy | It is reasonable to use similar indications for AF ablation in selected patients with HCM as in patients without HCM. | IIa | B-NR | [60–62] |
| Young patients (<45 years of age) | It is reasonable to use similar indications for AF ablation in young patients with AF (<45 years of age) as in older patients. | IIa | B-NR | [63, 64] |
| Tachy-brady syndrome | It is reasonable to offer AF ablation as an alternative to pacemaker implantation in patients with tachy-brady syndrome. | IIa | B-NR | [33–35] |
| Athletes with AF | It is reasonable to offer high-level athletes AF as first-line therapy due to the negative effects of medications on athletic performance. | IIa | C-LD | [27, 28, 65] |
| Asymptomatic AF** | Paroxysmal: Catheter ablation may be considered in select patients.** | IIb | C-EO | [66, 67] |
| | Persistent: Catheter ablation may be considered in select patients. | IIb | C-EO | [68] |

J Interv Card Electrophysiology 2017



Fibrillazione Atriale: L'ablazione quando e perchè



Ritmo sinusale meglio della FA

Intervenire nelle fasi iniziali e soprattutto nelle parossistiche

L'ablazione è una metodica efficace e sicura almeno quanto la terapia farmacologica

Accurata selezione dei pazienti



